{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:09:11Z","timestamp":1773011351493,"version":"3.50.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11864-009-0104-6","type":"journal-article","created":{"date-parts":[[2009,6,16]],"date-time":"2009-06-16T17:04:27Z","timestamp":1245171867000},"page":"126-140","source":"Crossref","is-referenced-by-count":123,"title":["Ewing\u2019s Sarcoma: Standard and Experimental Treatment Options"],"prefix":"10.1007","volume":"10","author":[{"given":"Vivek","family":"Subbiah","sequence":"first","affiliation":[]},{"given":"Pete","family":"Anderson","sequence":"additional","affiliation":[]},{"given":"Alexander J.","family":"Lazar","sequence":"additional","affiliation":[]},{"given":"Emily","family":"Burdett","sequence":"additional","affiliation":[]},{"given":"Kevin","family":"Raymond","sequence":"additional","affiliation":[]},{"given":"Joseph A.","family":"Ludwig","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,6,17]]},"reference":[{"issue":"4","key":"104_CR1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.mph.0000161762.53175.e4","volume":"27","author":"CE Herzog","year":"2005","unstructured":"Herzog, C.E., Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol, 2005. 27(4): p. 215-8. doi: 10.1097\/01.mph.0000161762.53175.e4 .","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"104_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3322\/canjclin.22.2.95","volume":"22","author":"J Ewing","year":"1972","unstructured":"Ewing, J., Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J Clin, 1972. 22(2): p. 95-8. doi: 10.3322\/canjclin.22.2.95 .","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"104_CR3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO;2-H","volume":"36","author":"L Angervall","year":"1975","unstructured":"Angervall, L. and F.M. Enzinger, Extraskeletal neoplasm resembling Ewing\u2019s sarcoma. Cancer, 1975. 36(1): p. 240-51. doi: 10.1002\/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO;2-H .","journal-title":"Cancer"},{"issue":"6","key":"104_CR4","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9","volume":"43","author":"FB Askin","year":"1979","unstructured":"Askin, F.B., et al., Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer, 1979. 43(6): p. 2438-51. doi: 10.1002\/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9 .","journal-title":"Cancer"},{"issue":"12","key":"104_CR5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00000478-198412000-00001","volume":"8","author":"R Jaffe","year":"1984","unstructured":"Jaffe, R., et al., The neuroectodermal tumor of bone. Am J Surg Pathol, 1984. 8(12): p. 885-98. doi: 10.1097\/00000478-198412000-00001 .","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"104_CR6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2000.18.1.204","volume":"18","author":"E Alava de","year":"2000","unstructured":"de Alava, E. and W.L. Gerald, Molecular biology of the Ewing\u2019s sarcoma\/primitive neuroectodermal tumor family. J Clin Oncol, 2000. 18(1): p. 204-13.","journal-title":"J Clin Oncol"},{"issue":"2","key":"104_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00148581-200810020-00004","volume":"10","author":"BM Seddon","year":"2008","unstructured":"Seddon, B.M. and J.S. Whelan, Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma. Paediatr Drugs, 2008. 10(2): p. 93-105. doi: 10.2165\/00148581-200810020-00004 .","journal-title":"Paediatr Drugs"},{"issue":"1","key":"104_CR8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MPH.0b013e31815cf71f","volume":"30","author":"SY Kim","year":"2008","unstructured":"Kim, S.Y., M. Tsokos, and L.J. Helman, Dilemmas associated with congenital ewing sarcoma family tumors. J Pediatr Hematol Oncol, 2008. 30(1): p. 4-7. doi: 10.1097\/MPH.0b013e31815cf71f .","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"104_CR9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/01.pas.0000167056.13614.62","volume":"29","author":"AL Folpe","year":"2005","unstructured":"Folpe, A.L., et al., Morphologic and immunophenotypic diversity in Ewing family tumors: a study of 66 genetically confirmed cases. Am J Surg Pathol, 2005. 29(8): p. 1025-33.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"104_CR10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.5858\/2006-130-1199-MDOS","volume":"130","author":"A Lazar","year":"2006","unstructured":"Lazar, A., et al., Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med, 2006. 130(8): p. 1199-207.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"104_CR11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1586\/14737159.8.1.97","volume":"8","author":"JD Khoury","year":"2008","unstructured":"Khoury, J.D., Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics. Expert Rev Mol Diagn, 2008. 8(1): p. 97-105. doi: 10.1586\/14737159.8.1.97 .","journal-title":"Expert Rev Mol Diagn"},{"issue":"5","key":"104_CR12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cncr.20059","volume":"100","author":"S Avigad","year":"2004","unstructured":"Avigad, S., et al., The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer, 2004. 100(5): p. 1053-8. doi: 10.1002\/cncr.20059 .","journal-title":"Cancer"},{"issue":"4","key":"104_CR13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1996.14.4.1245","volume":"14","author":"A Zoubek","year":"1996","unstructured":"Zoubek, A., et al., Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol, 1996. 14(4): p. 1245-51.","journal-title":"J Clin Oncol"},{"issue":"4","key":"104_CR14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.1998.16.4.1248","volume":"16","author":"E Alava de","year":"1998","unstructured":"de Alava, E., et al., EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing\u2019s sarcoma. J Clin Oncol, 1998. 16(4): p. 1248-55.","journal-title":"J Clin Oncol"},{"issue":"7","key":"104_CR15","first-page":"1428","volume":"59","author":"PP Lin","year":"1999","unstructured":"Lin, P.P., et al., Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing\u2019s sarcoma. Cancer Res, 1999. 59(7): p. 1428-32.","journal-title":"Cancer Res"},{"issue":"4","key":"104_CR16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/CCO.0b013e328303ba1d","volume":"20","author":"JA Ludwig","year":"2008","unstructured":"Ludwig, J.A., Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol, 2008. 20(4): p. 412-8.","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"104_CR17","first-page":"319","volume":"124","author":"S Falk","year":"1967","unstructured":"Falk, S. and M. Alpert, Five-year survival of patients with Ewing\u2019s sarcoma. Surg Gynecol Obstet, 1967. 124(2): p. 319-24.","journal-title":"Surg Gynecol Obstet"},{"key":"104_CR18","first-page":"55","volume":"23","author":"WW Sutow","year":"1962","unstructured":"Sutow, W.W. and M.P. Sullivan, Cyclophosphamide therapy in children with Ewing\u2019s sarcoma. Cancer Chemother Rep, 1962. 23: p. 55-60.","journal-title":"Cancer Chemother Rep"},{"key":"104_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1097-0142(196201\/02)15:1<42::AID-CNCR2820150107>3.0.CO;2-D","volume":"15","author":"D Pinkel","year":"1962","unstructured":"Pinkel, D., Cyclophosphamide in children with cancer. Cancer, 1962. 15: p. 42-9. doi: 10.1002\/1097-0142(196201\/02)15:1<42::AID-CNCR2820150107>3.0.CO;2-D .","journal-title":"Cancer"},{"issue":"1","key":"104_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/1097-0142(196901)23:1<161::AID-CNCR2820230121>3.0.CO;2-L","volume":"23","author":"R Johnson","year":"1969","unstructured":"Johnson, R. and S.R. Humphreys, Past failures and future possibilities in Ewing\u2019s sarcoma. Experimental and preliminary clinical results. Cancer, 1969. 23(1): p. 161-6. doi: 10.1002\/1097-0142(196901)23:1<161::AID-CNCR2820230121>3.0.CO;2-L .","journal-title":"Cancer"},{"issue":"2","key":"104_CR21","first-page":"103","volume":"54","author":"JJ Senyszyn","year":"1970","unstructured":"Senyszyn, J.J., R.E. Johnson, and R.E. Curran, Treatment of metastatic Ewing\u2019s sarcoma with actinomycin D (NSC-3053). Cancer Chemother Rep, 1970. 54(2): p. 103-7.","journal-title":"Cancer Chemother Rep"},{"issue":"6","key":"104_CR22","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/1097-0142(197212)30:6<1522::AID-CNCR2820300617>3.0.CO;2-J","volume":"30","author":"HO Hustu","year":"1972","unstructured":"Hustu, H.O., D. Pinkel, and C.B. Pratt, Treatment of clinically localized Ewing\u2019s sarcoma with radiotherapy and combination chemotherapy. Cancer, 1972. 30(6): p. 1522-7. doi: 10.1002\/1097-0142(197212)30:6<1522::AID-CNCR2820300617>3.0.CO;2-J .","journal-title":"Cancer"},{"issue":"5","key":"104_CR23","first-page":"635","volume":"56","author":"RK Oldham","year":"1972","unstructured":"Oldham, R.K. and T.C. Pomeroy, Treatment of Ewing\u2019s sarcoma with adriamycin (NSC-123127). Cancer Chemother Rep, 1972. 56(5): p. 635-9.","journal-title":"Cancer Chemother Rep"},{"issue":"2","key":"104_CR24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/1097-0142(197402)33:2<384::AID-CNCR2820330213>3.0.CO;2-T","volume":"33","author":"G Rosen","year":"1974","unstructured":"Rosen, G., et al., Proceedings: Disease-free survival in children with Ewing\u2019s sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer, 1974. 33(2): p. 384-93. doi: 10.1002\/1097-0142(197402)33:2<384::AID-CNCR2820330213>3.0.CO;2-T .","journal-title":"Cancer"},{"issue":"2","key":"104_CR25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1989.7.2.208","volume":"7","author":"FA Hayes","year":"1989","unstructured":"Hayes, F.A., et al., Therapy for localized Ewing\u2019s sarcoma of bone. J Clin Oncol, 1989. 7(2): p. 208-13.","journal-title":"J Clin Oncol"},{"issue":"1","key":"104_CR26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M","volume":"61","author":"H Jurgens","year":"1988","unstructured":"Jurgens, H., et al., Multidisciplinary treatment of primary Ewing\u2019s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer, 1988. 61(1): p. 23-32. doi: 10.1002\/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M .","journal-title":"Cancer"},{"issue":"3","key":"104_CR27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/1097-0142(19800801)46:3<516::AID-CNCR2820460316>3.0.CO;2-K","volume":"46","author":"A Razek","year":"1980","unstructured":"Razek, A., et al., Intergroup Ewing\u2019s Sarcoma Study: local control related to radiation dose, volume, and site of primary lesion in Ewing\u2019s sarcoma. Cancer, 1980. 46(3): p. 516-21. doi: 10.1002\/1097-0142(19800801)46:3<516::AID-CNCR2820460316>3.0.CO;2-K .","journal-title":"Cancer"},{"issue":"8","key":"104_CR28","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","volume":"348","author":"HE Grier","year":"2003","unstructured":"Grier, H.E., et al., Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med, 2003. 348(8): p. 694-701. doi: 10.1056\/NEJMoa020890 .","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"104_CR29","doi-asserted-by":"crossref","first-page":"ii97","DOI":"10.1093\/annonc\/mdn103","volume":"19","author":"M Paulussen","year":"2008","unstructured":"Paulussen, M., et al., Ewing\u2019s sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 2008. 19 Suppl 2: p. ii97-8. doi: 10.1093\/annonc\/mdn103 .","journal-title":"Ann Oncol"},{"key":"104_CR30","doi-asserted-by":"crossref","unstructured":"Womer RB, West DC, Krailo MD, Dickman PS, Pawel B, for the Children\u2019s Oncology Group AEWS0031 Committee: Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol 2008, 26(May 20 suppl; abstr 10504)","DOI":"10.1200\/jco.2008.26.15_suppl.10504"},{"issue":"5","key":"104_CR31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21917","volume":"52","author":"S Ferrari","year":"2009","unstructured":"Ferrari, S, et al.: Response to high-dose ifosfamide in patients with advanced\/recurrent Ewing sarcoma. Pediatr Blood Cancer 2009","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"104_CR32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/pbc.21657","volume":"51","author":"S Laskar","year":"2008","unstructured":"Laskar, S., et al., Post-operative radiotherapy for Ewing sarcoma: when, how and how much? Pediatr Blood Cancer, 2008. 51(5): p. 575-80. doi: 10.1002\/pbc.21657 .","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"104_CR33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ijrobp.2008.02.023","volume":"72","author":"DJ Indelicato","year":"2008","unstructured":"Indelicato, D.J., et al., Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys, 2008. 72(3): p. 871-7. doi: 10.1016\/j.ijrobp.2008.02.023 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"104_CR34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijrobp.2007.06.032","volume":"70","author":"DJ Indelicato","year":"2008","unstructured":"Indelicato, D.J., et al., Long-term clinical and functional outcomes after treatment for localized Ewing\u2019s tumor of the lower extremity. Int J Radiat Oncol Biol Phys, 2008. 70(2): p. 501-9. doi: 10.1016\/j.ijrobp.2007.06.032 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"104_CR35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0360-3016(02)03797-5","volume":"55","author":"A Schuck","year":"2003","unstructured":"Schuck, A., et al., Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys, 2003. 55(1): p. 168-77. doi: 10.1016\/S0360-3016(02)03797-5 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"104_CR36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2003.08.022","volume":"40","author":"G Bacci","year":"2004","unstructured":"Bacci, G., et al., Long-term outcome for patients with non-metastatic Ewing\u2019s sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer, 2004. 40(1): p. 73-83. doi: 10.1016\/j.ejca.2003.08.022 .","journal-title":"Eur J Cancer"},{"issue":"1","key":"104_CR37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0360-3016(98)00191-6","volume":"42","author":"SS Donaldson","year":"1998","unstructured":"Donaldson, S.S., et al., A multidisciplinary study investigating radiotherapy in Ewing\u2019s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys, 1998. 42(1): p. 125-35. doi: 10.1016\/S0360-3016(98)00191-6 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"104_CR38","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ijrobp.2004.04.006","volume":"60","author":"MJ Krasin","year":"2004","unstructured":"Krasin, M.J., et al., Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys, 2004. 60(3): p. 830-8. doi: 10.1016\/j.ijrobp.2004.04.006 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"104_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/pbc.10472","volume":"42","author":"SS Donaldson","year":"2004","unstructured":"Donaldson, S.S., Ewing sarcoma: radiation dose and target volume. Pediatr Blood Cancer, 2004. 42(5): p. 471-6. doi: 10.1002\/pbc.10472 .","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"104_CR40","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1200\/JCO.2000.18.17.3108","volume":"18","author":"SJ Cotterill","year":"2000","unstructured":"Cotterill, S.J., et al., Prognostic factors in Ewing\u2019s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing\u2019s Sarcoma Study Group. J Clin Oncol, 2000. 18(17): p. 3108-14.","journal-title":"J Clin Oncol"},{"issue":"18","key":"104_CR41","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.2003.10.033","volume":"21","author":"EA Kolb","year":"2003","unstructured":"Kolb, E.A., et al., Long-term event-free survival after intensive chemotherapy for Ewing\u2019s family of tumors in children and young adults. J Clin Oncol, 2003. 21(18): p. 3423-30. doi: 10.1200\/JCO.2003.10.033 .","journal-title":"J Clin Oncol"},{"issue":"2","key":"104_CR42","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000225417","volume":"37","author":"JG Sinkovics","year":"1980","unstructured":"Sinkovics, J.G., et al., Ewing sarcoma: its course and treatment in 50 adult patients. Oncology, 1980. 37(2): p. 114-9.","journal-title":"Oncology"},{"issue":"6","key":"104_CR43","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00000421-198812000-00003","volume":"11","author":"RD Siegel","year":"1988","unstructured":"Siegel, R.D., L.M. Ryan, and K.H. Antman, Adults with Ewing\u2019s sarcoma. An analysis of 16 patients at the Dana-Farber Cancer Institute. Am J Clin Oncol, 1988. 11(6): p. 614-7. doi: 10.1097\/00000421-198812000-00003 .","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"104_CR44","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.1997.15.4.1553","volume":"15","author":"P Picci","year":"1997","unstructured":"Picci, P., et al., Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing\u2019s sarcoma of the extremities. J Clin Oncol, 1997. 15(4): p. 1553-9.","journal-title":"J Clin Oncol"},{"issue":"7","key":"104_CR45","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1200\/JCO.1997.15.7.2611","volume":"15","author":"MW Verrill","year":"1997","unstructured":"Verrill, M.W., et al., Ewing\u2019s sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing\u2019s sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol, 1997. 15(7): p. 2611-21.","journal-title":"J Clin Oncol"},{"issue":"12","key":"104_CR46","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.1998.16.12.3736","volume":"16","author":"K Fizazi","year":"1998","unstructured":"Fizazi, K., et al., Ewing\u2019s family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol, 1998. 16(12): p. 3736-43.","journal-title":"J\u2423Clin Oncol"},{"issue":"4","key":"104_CR47","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/cncr.22456","volume":"109","author":"G Bacci","year":"2007","unstructured":"Bacci, G., et al., Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer, 2007. 109(4): p. 780-6. doi: 10.1002\/cncr.22456 .","journal-title":"Cancer"},{"issue":"12","key":"104_CR48","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1159\/000165361","volume":"31","author":"S Pieper","year":"2008","unstructured":"Pieper, S., et al., Ewing\u2019s tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99. Onkologie, 2008. 31(12): p. 657-63. doi: 10.1159\/000165361 .","journal-title":"Onkologie"},{"key":"104_CR49","unstructured":"Paulussen M, Ahrens S, Juergens HF: Cure rates in Ewing tumor patients aged over 15\u00a0years are better in pediatric oncology units. Results of GPOH CESS\/EICESS studies. ASCO 2003 Annual Meeting 2003"},{"issue":"1","key":"104_CR50","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1148\/radiol.2281011651","volume":"228","author":"JP Dyke","year":"2003","unstructured":"Dyke, J.P., et al., Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology, 2003. 228(1): p. 271-8. doi: 10.1148\/radiol.2281011651 .","journal-title":"Radiology"},{"issue":"4","key":"104_CR51","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1586\/14737140.8.4.617","volume":"8","author":"PJ Leavey","year":"2008","unstructured":"Leavey, P.J. and A.B. Collier, Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther, 2008. 8(4): p. 617-24. doi: 10.1586\/14737140.8.4.617 .","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"104_CR52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPH.0b013e31816e22f3","volume":"30","author":"N Esiashvili","year":"2008","unstructured":"Esiashvili, N., M. Goodman, and R.B. Marcus, Jr., Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol, 2008. 30(6): p. 425-30. doi: 10.1097\/MPH.0b013e31816e22f3 .","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"104_CR53","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/pbc.21618","volume":"51","author":"PJ Leavey","year":"2008","unstructured":"Leavey, P.J., et al., Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children\u2019s Oncology Group. Pediatr Blood Cancer, 2008. 51(3): p. 334-8. doi: 10.1002\/pbc.21618 .","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"104_CR54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-3476(68)80078-2","volume":"73","author":"HO Hustu","year":"1968","unstructured":"Hustu, H.O., et al., Treatment of Ewing\u2019s sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr, 1968. 73(2): p. 249-51. doi: 10.1016\/S0022-3476(68)80078-2 .","journal-title":"J Pediatr"},{"issue":"15","key":"104_CR55","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1200\/JCO.2001.19.15.3463","volume":"19","author":"RL Saylors 3rd","year":"2001","unstructured":"Saylors, R.L., 3rd, et al., Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol, 2001. 19(15): p. 3463-9.","journal-title":"J Clin Oncol"},{"issue":"6","key":"104_CR56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pbc.20719","volume":"47","author":"A Hunold","year":"2006","unstructured":"Hunold, A., et al., Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer, 2006. 47(6): p. 795-800. doi: 10.1002\/pbc.20719 .","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"104_CR57","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1517\/13543784.17.11.1703","volume":"17","author":"P Anderson","year":"2008","unstructured":"Anderson, P., et al., Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing\u2019s sarcoma and osteosarcoma). Expert Opin Investig Drugs, 2008. 17(11): p. 1703-15. doi: 10.1517\/13543784.17.11.1703 .","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"104_CR58","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1078-0432.CCR-03-0175","volume":"10","author":"LM Wagner","year":"2004","unstructured":"Wagner, L.M., et al., Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res, 2004. 10(3): p. 840-8. doi: 10.1158\/1078-0432.CCR-03-0175 .","journal-title":"Clin Cancer Res"},{"issue":"2","key":"104_CR59","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pbc.20697","volume":"48","author":"LM Wagner","year":"2007","unstructured":"Wagner, L.M., et al., Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer, 2007. 48(2): p. 132-9. doi: 10.1002\/pbc.20697 .","journal-title":"Pediatr Blood Cancer"},{"issue":"33","key":"104_CR60","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1200\/JCO.2006.06.7272","volume":"24","author":"BH Kushner","year":"2006","unstructured":"Kushner, B.H., et al., Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol, 2006. 24(33): p. 5271-6. doi: 10.1200\/JCO.2006.06.7272 .","journal-title":"J Clin Oncol"},{"issue":"19","key":"104_CR61","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki, R.G., et al., Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol, 2007. 25(19): p. 2755-63. doi: 10.1200\/JCO.2006.10.4117 .","journal-title":"J Clin Oncol"},{"issue":"11","key":"104_CR62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrc1739","volume":"5","author":"JA Ludwig","year":"2005","unstructured":"Ludwig, J.A. and J.N. Weinstein, Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer, 2005. 5(11): p. 845-56. doi: 10.1038\/nrc1739 .","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"104_CR63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.6004\/jnccn.2007.0039","volume":"5","author":"SM Schuetze","year":"2007","unstructured":"Schuetze, S.M., Chemotherapy in the management of osteosarcoma and Ewing\u2019s sarcoma. J Natl Compr Canc Netw, 2007. 5(4): p. 449-55.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"104_CR64","first-page":"697","volume":"15","author":"R Ladenstein","year":"1995","unstructured":"Ladenstein, R., et al., Impact of megatherapy in children with high-risk Ewing\u2019s tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant, 1995. 15(5): p. 697-705.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"104_CR65","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1008208511815","volume":"9","author":"M Paulussen","year":"1998","unstructured":"Paulussen, M., et al., Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol, 1998. 9(3): p. 275-81. doi: 10.1023\/A:1008208511815 .","journal-title":"Ann Oncol"},{"issue":"11","key":"104_CR66","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1023\/A:1026539908115","volume":"11","author":"S Burdach","year":"2000","unstructured":"Burdach, S., et al., Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol, 2000. 11(11): p. 1451-62. doi: 10.1023\/A:1026539908115 .","journal-title":"Ann Oncol"},{"issue":"11","key":"104_CR67","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2001.19.11.2812","volume":"19","author":"PA Meyers","year":"2001","unstructured":"Meyers, P.A., et al., High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing\u2019s sarcoma does not improve prognosis. J Clin Oncol, 2001. 19(11): p. 2812-20.","journal-title":"J Clin Oncol"},{"issue":"16","key":"104_CR68","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1200\/JCO.2003.12.039","volume":"21","author":"S Burdach","year":"2003","unstructured":"Burdach, S., et al., High-dose therapy for patients with primary multifocal and early relapsed Ewing\u2019s tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol, 2003. 21(16): p. 3072-8. doi: 10.1200\/JCO.2003.12.039 .","journal-title":"J Clin Oncol"},{"issue":"1","key":"104_CR69","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2006-01-023101","volume":"109","author":"S Bhatia","year":"2007","unstructured":"Bhatia, S., et al., Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children\u2019s Oncology Group. Blood, 2007. 109(1): p. 46-51. doi: 10.1182\/blood-2006-01-023101 .","journal-title":"Blood"},{"issue":"12","key":"104_CR70","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bmt.2008.26","volume":"41","author":"A Hosono","year":"2008","unstructured":"Hosono A, et al.: Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing\u2019s sarcoma family of tumors. Bone Marrow Transplant 2008","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"104_CR71","first-page":"3622","volume":"8","author":"MF Bolontrade","year":"2002","unstructured":"Bolontrade, M.F., R.R. Zhou, and E.S. Kleinerman, Vasculogenesis Plays a Role in the Growth of Ewing\u2019s Sarcoma in Vivo. Clin Cancer Res, 2002. 8(11): p. 3622-7.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"104_CR72","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-03-0038","volume":"10","author":"B Fuchs","year":"2004","unstructured":"Fuchs, B., C.Y. Inwards, and R. Janknecht, Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing\u2019s sarcoma. Clin Cancer Res, 2004. 10(4): p. 1344-53. doi: 10.1158\/1078-0432.CCR-03-0038 .","journal-title":"Clin Cancer Res"},{"issue":"8","key":"104_CR73","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2004.02.098","volume":"22","author":"R Garcia-Carbonero","year":"2004","unstructured":"Garcia-Carbonero, R., et al., Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol, 2004. 22(8): p. 1480-90. doi: 10.1200\/JCO.2004.02.098 .","journal-title":"J Clin Oncol"},{"issue":"23","key":"104_CR74","doi-asserted-by":"crossref","first-page":"11456","DOI":"10.1073\/pnas.89.23.11456","volume":"89","author":"R Sakai","year":"1992","unstructured":"Sakai, R., et al., Additional antitumor ecteinascidins from a Caribbean tunicate: crystal structures and activities in vivo. Proc Natl Acad Sci U S A, 1992. 89(23): p. 11456-60. doi: 10.1073\/pnas.89.23.11456 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"104_CR75","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1158\/1535-7163.MCT-04-0316","volume":"4","author":"N Martinez","year":"2005","unstructured":"Martinez, N., et al., Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther, 2005. 4(5): p. 814-23. doi: 10.1158\/1535-7163.MCT-04-0316 .","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"104_CR76","first-page":"429","volume":"7","author":"H Kovar","year":"1996","unstructured":"Kovar, H., et al., EWS\/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ, 1996. 7(4): p. 429-37.","journal-title":"Cell Growth Differ"},{"issue":"2","key":"104_CR77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1172\/JCI119152","volume":"99","author":"K Tanaka","year":"1997","unstructured":"Tanaka, K., et al., EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing\u2019s sarcoma and primitive neuroectodermal tumor cells. J Clin Invest, 1997. 99(2): p. 239-47. doi: 10.1172\/JCI119152 .","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"104_CR78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1023\/A:1005716926800","volume":"31","author":"JA Toretsky","year":"1997","unstructured":"Toretsky, J.A., et al., Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol, 1997. 31(1-2): p. 9-16. doi: 10.1023\/A:1005716926800 .","journal-title":"J Neurooncol"},{"issue":"2","key":"104_CR79","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/bbrc.2000.3963","volume":"279","author":"G Lambert","year":"2000","unstructured":"Lambert, G., et al., EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun, 2000. 279(2): p. 401-6. doi: 10.1006\/bbrc.2000.3963 .","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"104_CR80","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1371\/journal.pmed.0040122","volume":"4","author":"K Stegmaier","year":"2007","unstructured":"Stegmaier, K., et al., Signature-based small molecule screening identifies cytosine arabinoside as an EWS\/FLI modulator in Ewing sarcoma. PLoS Med, 2007. 4(4): p. e122. doi: 10.1371\/journal.pmed.0040122 .","journal-title":"PLoS Med"},{"issue":"3","key":"104_CR81","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/pbc.21822","volume":"52","author":"SG DuBois","year":"2009","unstructured":"DuBois, S.G., et al., Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer, 2009. 52(3): p. 324-7. doi: 10.1002\/pbc.21822 .","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"104_CR82","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/path.2499","volume":"217","author":"B Rikhof","year":"2009","unstructured":"Rikhof B, et al.: The insulin-like growth factor system and sarcomas. J Pathol 2008","journal-title":"J Pathol"},{"issue":"49","key":"104_CR83","doi-asserted-by":"crossref","first-page":"30822","DOI":"10.1074\/jbc.272.49.30822","volume":"272","author":"JA Toretsky","year":"1997","unstructured":"Toretsky, J.A., et al., The insulin-like growth factor-I receptor is required for EWS\/FLI-1 transformation of fibroblasts. J Biol Chem, 1997. 272(49): p. 30822-7. doi: 10.1074\/jbc.272.49.30822 .","journal-title":"J Biol Chem"},{"issue":"20","key":"104_CR84","first-page":"4570","volume":"56","author":"K Scotlandi","year":"1996","unstructured":"Scotlandi, K., et al., Insulin-like growth factor I receptor-mediated circuit in Ewing\u2019s sarcoma\/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res, 1996. 56(20): p. 4570-4.","journal-title":"Cancer Res"},{"issue":"16","key":"104_CR85","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1128\/MCB.24.16.7275-7283.2004","volume":"24","author":"A Prieur","year":"2004","unstructured":"Prieur, A., et al., EWS\/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol, 2004. 24(16): p. 7275-83. doi: 10.1128\/MCB.24.16.7275-7283.2004 .","journal-title":"Mol Cell Biol"},{"issue":"3","key":"104_CR86","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ijc.11576","volume":"108","author":"S Benini","year":"2004","unstructured":"Benini, S., et al., Contribution of MEK\/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing\u2019s sarcoma cells: therapeutic prospects. Int J Cancer, 2004. 108(3): p. 358-66. doi: 10.1002\/ijc.11576 .","journal-title":"Int J Cancer"},{"issue":"4","key":"104_CR87","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1078-0432.CCR-06-1518","volume":"13","author":"MC Manara","year":"2007","unstructured":"Manara, M.C., et al., Preclinical in vivo study of new insulin-like growth factor-I receptor\u2013specific inhibitor in Ewing\u2019s sarcoma. Clin Cancer Res, 2007. 13(4): p. 1322-30. doi: 10.1158\/1078-0432.CCR-06-1518 .","journal-title":"Clin Cancer Res"},{"key":"104_CR88","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2867-8-16","volume":"8","author":"A Hurtubise","year":"2008","unstructured":"Hurtubise, A., M.L. Bernstein, and R.L. Momparler, Preclinical evaluation of the antineoplastic action of 5-aza-2\u2019-deoxycytidine and different histone deacetylase inhibitors on human Ewing\u2019s sarcoma cells. Cancer Cell Int, 2008. 8: p. 16. doi: 10.1186\/1475-2867-8-16 .","journal-title":"Cancer Cell Int"},{"issue":"4","key":"104_CR89","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ejca.2008.11.045","volume":"45","author":"S Dalal","year":"2009","unstructured":"Dalal S, Burchill SA: Preclinical evaluation of vascular-disrupting agents in Ewing\u2019s sarcoma family of tumours. Eur J Cancer 2009","journal-title":"Eur J Cancer"},{"issue":"16","key":"104_CR90","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1158\/1078-0432.CCR-07-0133","volume":"13","author":"Z Zhou","year":"2007","unstructured":"Zhou, Z., et al., Suppression of Ewing\u2019s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res, 2007. 13(16): p. 4867-73. doi: 10.1158\/1078-0432.CCR-07-0133 .","journal-title":"Clin Cancer Res"},{"issue":"5","key":"104_CR91","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ejca.2008.01.020","volume":"44","author":"KL Schaefer","year":"2008","unstructured":"Schaefer KL, et al.: Microarray analysis of Ewing\u2019s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer 2008","journal-title":"Eur J Cancer"},{"issue":"3","key":"104_CR92","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/pbc.20124","volume":"43","author":"A Uren","year":"2004","unstructured":"Uren, A., et al., Wnt\/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer, 2004. 43(3): p. 243-9. doi: 10.1002\/pbc.20124 .","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"104_CR93","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/sj.onc.1210991","volume":"27","author":"JP Zwerner","year":"2008","unstructured":"Zwerner JP, et al.: The EWS\/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2007","journal-title":"Oncogene"},{"issue":"4","key":"104_CR94","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.semdp.2008.07.005","volume":"25","author":"JL Ordonez","year":"2008","unstructured":"Ordonez, J.L., et al., Targeting sarcomas: therapeutic targets and their rational. Semin Diagn Pathol, 2008. 25(4): p. 304-16. doi: 10.1053\/j.semdp.2008.07.005 .","journal-title":"Semin Diagn Pathol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-009-0104-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-009-0104-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-009-0104-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T11:56:51Z","timestamp":1633607811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-009-0104-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":94,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["104"],"URL":"https:\/\/doi.org\/10.1007\/s11864-009-0104-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}